Neurotech International Ltd (AU:NTI) — Market Cap & Net Worth
Market Cap & Net Worth: Neurotech International Ltd (NTI)
Neurotech International Ltd (AU:NTI) has a market capitalization of $14.92 Million (AU$21.08 Million) as of August 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25975 globally and #1155 in its home market, demonstrating a -5.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurotech International Ltd's stock price AU$0.02 by its total outstanding shares 1317741687 (1.32 Billion). Review Neurotech International Ltd debt and liabilities to assess the company's total debt and financial obligations.
Neurotech International Ltd Market Cap History: 2016 to 2026
Neurotech International Ltd's market capitalization history from 2016 to 2026. Data shows change from $314.12 Million to $14.92 Million (-24.55% CAGR).
Neurotech International Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurotech International Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.34x
Neurotech International Ltd's market cap is 5.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $314.12 Million | $126.67K | -$2.18 Million | 2479.90x | N/A |
| 2017 | $163.17 Million | $88.31K | -$4.03 Million | 1847.67x | N/A |
| 2018 | $36.74 Million | $30.05K | -$3.99 Million | 1222.62x | N/A |
| 2019 | $14.92 Million | $194.56K | -$4.80 Million | 76.68x | N/A |
| 2020 | $41.96 Million | $77.37K | -$1.71 Million | 542.32x | N/A |
| 2021 | $55.94 Million | $206.14K | -$7.43 Million | 271.38x | N/A |
| 2022 | $64.33 Million | $38.26K | -$3.36 Million | 1681.42x | N/A |
| 2023 | $64.33 Million | $5.96K | -$7.79 Million | 10796.22x | N/A |
| 2024 | $51.28 Million | $1.96K | -$5.07 Million | 26123.91x | N/A |
| 2025 | $13.05 Million | $2.44 Million | -$10.60 Million | 5.34x | N/A |
Competitor Companies of NTI by Market Capitalization
Companies near Neurotech International Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Neurotech International Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Neurotech International Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Neurotech International Ltd's market cap moved from $314.12 Million to $ 14.92 Million, with a yearly change of -24.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$14.92 Million | +14.29% |
| 2025 | AU$13.05 Million | -74.55% |
| 2024 | AU$51.28 Million | -20.29% |
| 2023 | AU$64.33 Million | 0.00% |
| 2022 | AU$64.33 Million | +15.00% |
| 2021 | AU$55.94 Million | +33.33% |
| 2020 | AU$41.96 Million | +181.25% |
| 2019 | AU$14.92 Million | -59.39% |
| 2018 | AU$36.74 Million | -77.49% |
| 2017 | AU$163.17 Million | -48.06% |
| 2016 | AU$314.12 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Neurotech International Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.92 Million USD |
| MoneyControl | $14.92 Million USD |
| MarketWatch | $14.92 Million USD |
| marketcap.company | $14.92 Million USD |
| Reuters | $14.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more